McGuff Pharmacy Blog and News

Our Latest News.

Congress has Listened to YOUR Compounding Drug Concerns and Followed Through!

Congress has Listened to YOUR Compounding Drug Concerns and Followed Through!

I know the words ‘United States Congress’ and ‘Follow Through’ are generally never used in the same sentence, but in this case it actually just happened! Your letters sent to Congress via our website have paid off...

Read More


Ask your Representatives to Sign Rep. Stewart / Carter Letter to FDA regarding office-use

Ask your Representatives to Sign Rep. Stewart / Carter Letter to FDA regarding office-use

On December 29, 2016, the Food & Drug Administration (FDA) issued a final Guidance for Industry (GFI) which continues to completely prohibit office-use compounding under state pharmacy laws. This guidance is a misinterpretation of the 2013 Drug Quality and Security Act (DQSA) regarding office-use compounding. Additionally, the FDA has unfortunately chosen to ignore broad and diverse stakeholder input, multiple congressional letters from both chambers, and clear directives in the House Report accompanying the FY2016 FDA appropriations legislation. This Guidance is VERY detrimental for patients and doctors to access compounded medications...

Read More


U.S. Congressman and Pharmacist Buddy Carter (R-GA) Appointed to the Energy and Commerce Committee

U.S. Congressman and Pharmacist Buddy Carter (R-GA) Appointed to the Energy and Commerce Committee

In 2016 McGuff Compounding Pharmacy Services, Inc. provided the maximum legal funding to Congressman Buddy Carter to help assure the Congressman obtain his long-term goal of serving on the House Energy and Commerce Committee which oversees FDA. “Buddy” desires FDA to conform to law and not revise congressional intent. Buddy’s appointment will be great for physicians, patients and pharmacists.

Read More


Compounding Pharmacy and Loss of Interstate Dispensing

Compounding Pharmacy and Loss of Interstate Dispensing

Through everyone’s action on the “Ask Your U.S. Congressional Representatives to Sign onto Representative Stewart and Representative Cuellar’s letter to the FDA on Compounding Pharmacies,” we were able to increase the number of United States Congressmen signatures on the letter from 19 to 61! This was an amazing undertaking and on behalf of McGuff Compounding Pharmacy Services, Inc., I would like to personally thank each and every one of you who participated. The letter has since been sent to the FDA on June 20, 2016.

Currently, the largest impediment to your receiving compounded drugs...

Read More


FDA has opened a Public Docket on Drug Compounding where they are asking for your comments

FDA has opened a Public Docket on Drug Compounding where they are asking for your comments

Do you have ideas, opinions, and thoughts for the FDA about compounding pharmacies? Well if you do, the FDA has opened a Public Docket on Drug Compounding where they are asking for your comments. A FDA notice to industry states that comments by the public...

Read More


Watch Now - FDA Pharmacy Compounding Advisory Committee voting to approve the compounding of DMPS

Watch Now - FDA Pharmacy Compounding Advisory Committee voting to approve the compounding of DMPS

Watch and listen to the June 23, 2016 FDA Pharmacy Compounding Advisory Committee discussions on DMPS and presentations given....

Read More


FDA Pharmacy Compounding Advisory Committee voted to approve the compounding of DMPS

FDA Pharmacy Compounding Advisory Committee voted to approve the compounding of DMPS

We are very pleased to announce that the FDA Pharmacy Compounding Advisory Committee on June 23, 2016 voted 8-3 to approve the compounding of DMPS, going against the FDA staff recommendation. The Committee favored having an effective intravenous IV chelator, understanding that DMPS is needed to save lives...

Read More


McGuff Compounding Pharmacy has been invited by the FDA to make a presentation to PCAC supporting the nomination of DMPS

June 23, 2016 Webcast of the Pharmacy Compounding Advisory Committee on DMPS

As you have probably heard recently from one of our Blog posts/Emails, the FDA is proposing to the Pharmacy Compounding Advisory Committee (PCAC) to not approve DMPS on the Bulk Drug Substances List for 503A compounding pharmacies. Meaning that if the FDA gets their way, DMPS will no longer be available to you. ...

Read More


McGuff Compounding Pharmacy has been invited by the FDA to make a presentation to PCAC supporting the nomination of DMPS

"FDA is proposing that DMPS (2, 3-dimercapto-1-propanesulfonic acid) NOT be placed on the 503A bulk list…”

If the FDA gets their way, DMPS will not be added to the Bulk Drug Substance List and DMPS will no longer be available through compounding pharmacies… at all. Later this month the FDA’s Pharmacy Compounding Advisory Committee (PCAC) will meet to determine if the committee will approve - or not approve - DMPS being ...

Read More


Standard Post with Image

McGuff Company named one of the top places to work in Orange County for the second year in a row

Taking the time to get to know employees on a personal level has helped foster pharmaceutical firm's thriving atmosphere.

Read More


Standard Post with Image

Production of Sodium Chloride IV Bags continues to struggle

As a responsible medical supplier, we believe in transparency so we can keep our customers and potential customers at the forefront of issues that may affect your day to day operations.

Read More

Prescription Center

With a McGuff account you can:

  • Refill prescriptions with a
        few clicks of the mouse!
  • Print invoices
  • View your order history


McGuff was named a Top Workplace of 2014 by the Orange County Register